LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
DexCom’s fair value price target has been tweaked from US$85.85 to US$86.12 per share, a small shift that still matters if you are tracking what analysts are baking into their models. This move sits ...
If you are wondering whether DexCom's current share price lines up with its underlying worth, or if the market is mispricing ...
“The approval of Dexcom G7 15 Day marks another major innovation for Dexcom,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “By listening to the needs of our users, ...
Now through Sept. 19, people in the U.S. and Canada from 2 years and older living with all types of diabetes and prediabetes can apply for a once-in-a-lifetime opportunity to raise diabetes awareness ...
DexCom treats about 2.5 million patients, with tons of room for more. The company's Q2 guidance bombshell tanked the stock. Competition from an unexpected source raises long-term concerns worth ...
Mr. Leach begins his inaugural year as CEO with speaking engagements at CES 2026 and the 44th annual J.P. Morgan Healthcare Conference A completely reimagined Stelo app experience will launch this ...
Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company’s one-of-a-kind NIL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results